Skip to main content
Sino Medical Sciences Technology Inc. logo

Sino Medical Sciences Technology Inc. — Investor Relations & Filings

Ticker · 688108 ISIN · CNE100003NY2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688108

About Sino Medical Sciences Technology Inc.

https://www.sinomed.com/

Sino Medical Sciences Technology Inc. (SINOMED) specializes in the research, development, and manufacturing of high-end interventional medical devices. The company focuses on cardiovascular, neurovascular, and structural heart disease treatments. Its core product portfolio includes drug-eluting stents (DES) and balloon catheters, notably the BuMA and BuMA Supreme series. SINOMED utilizes proprietary technologies, such as the eG™ coating, to improve clinical outcomes and patient safety. The company maintains a strong commitment to clinical research and international expansion, aiming to provide innovative solutions for minimally invasive procedures.

Recent filings

Filing Released Lang Actions
赛诺医疗科学技术股份有限公司关于公司冠脉支架产品全人群双抗疗程缩短至1个月获欧盟批准的自愿性披露公告
Regulatory Filings Classification · 80% confidence The document is a voluntary disclosure announcement regarding the EU regulatory approval for the company’s HT Supreme™ drug-eluting stent and the change in recommended DAPT duration. It does not contain financial statements, management discussion, dividend details, or capital transactions. It is a general regulatory announcement (non-financial), fitting the fallback category “Regulatory Filings” (RNS).
2026-05-20 Chinese
赛诺医疗科学技术股份有限公司关于第三届董事会独立董事专门会议第十三次会议决议的公告
Regulatory Filings Classification · 84% confidence The document is an announcement of the independent directors’ specialized board meeting resolution approving a related-party borrowing by the US subsidiary. It does not report management changes (MANG), shareholder meeting voting results (DVA), or financial statements. It also is not a formal financial report or presentation, but a routine corporate announcement. Therefore it falls under the general Regulatory Filings category (RNS).
2026-05-15 Chinese
赛诺医疗科学技术股份有限公司关于美国子公司eLum向关联方追加借款暨关联交易的公告
Capital/Financing Update Classification · 85% confidence The document is an official exchange announcement disclosing and approving a related-party loan transaction by the company’s US subsidiary. It details terms of an incremental borrowing facility, approval procedures by the board and committees, and the loan agreement’s key terms. This is a financing activity update rather than a full report, management changes, or regulatory compliance filing. Therefore, it falls under the Capital/Financing Update category (CAP).
2026-05-15 Chinese
赛诺医疗科学技术股份有限公司关于第三届董事会第十七次会议决议的公告
Board/Management Information Classification · 75% confidence The document is an official announcement of the board of directors’ meeting resolutions (third board’s 17th meeting) including approval of a related‐party loan transaction. It does not contain financial statements, dividend info, or audit data, nor is it a report publication notice. This type of corporate governance disclosure—board meeting resolutions—is classified under Board/Management Information (MANG).
2026-05-15 Chinese
2026-053：赛诺医疗科学技术股份有限公司关于股份回购实施结果暨股份变动的公告
Transaction in Own Shares Classification · 95% confidence The document is a corporate announcement detailing the implementation results of the company's share repurchase plan, including the number of shares bought back, purchase price range, impact on share capital, and follow-up arrangements. This is a clear report of the company’s own share transactions (buyback). Therefore it falls under Transaction in Own Shares (POS).
2026-05-13 Chinese
赛诺医疗科学技术股份有限公司关于股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company about the progress of its share repurchase program. It includes details such as the repurchase plan, implementation period, expected repurchase amount, purpose, and the current status of repurchases (none done yet). The document is relatively short (1103 characters) and focuses on the update of share buyback activities rather than presenting financial statements or detailed financial analysis. It does not contain financial results or management discussion but is a formal disclosure of share repurchase progress. Therefore, it fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2026-05-06 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.